223514-69-0

Usage

Uses

Used in Pharmaceutical Industry:
(R)-N-(1-(4-hydroxymethylphenyl)ethyl)acetamide is used as a building block for the synthesis of pharmaceuticals because of its unique structure and properties. Its chiral center allows for the creation of various enantiomers, which can have different biological activities and therapeutic effects.
Used in Medicinal Chemistry Research:
In the field of medicinal chemistry, (R)-N-(1-(4-hydroxymethylphenyl)ethyl)acetamide is used as a key component in the development of new drugs. Its amide structure and chiral center provide a foundation for designing and synthesizing novel compounds with potential therapeutic applications.
Used in Pain Management:
(R)-N-(1-(4-hydroxymethylphenyl)ethyl)acetamide is used as an analgesic agent, helping to alleviate pain by interacting with the body's pain receptors and pathways. Its effectiveness in pain management makes it a promising candidate for the development of new pain relief medications.
Used in Anti-Inflammatory Applications:
(R)-N-(1-(4-hydroxymethylphenyl)ethyl)acetamide is also used for its anti-inflammatory properties, which can help reduce inflammation and associated discomfort in various conditions. Its potential use in anti-inflammatory drugs highlights the versatility of (R)-N-(1-(4-hydroxymethylphenyl)ethyl)acetamide in the realm of medicinal chemistry and pharmacology.

Upstream product

• 859163-61-4 (R)-4-(1-acetamidoethyl)benzoic acid 
• 88146-37-6 (R)-N-(1-(4-acetylphenyl)ethyl)acetamide 
• 36283-44-0 N-acetyl-1-phenylethylamine 
• 3886-69-9 (R)-1-phenyl-ethyl-amine 
• 173898-18-5 (R)-N-(4-methoxycarbonylphenylethyl)acetamide 

Downstream Products

• 223514-71-4 (R)-N-(1-(4-chloromethylphenyl)ethyl)acetamide 

Relevant academic research and scientific papers

Piperazine compounds and medicinal use thereof

The present invention relates to a piperazine compound of the formula wherein R1and R2are each hydrogen, halogen, lower alkyl, lower alkoxy, amino, substituted amino, nitro, hydroxy or cyano, R3, R4and R5are each hydrogen, halogen, lower alkyl, lower alkoxy, nitro, amino, substituted amino or hydroxy, R6and R7are each hydrogen, lower alkyl, lower alkyl substituted by halogen, aralkyl, acyl or lower acyl substituted by halogen, R8and R9are each hydrogen or lower alkyl, Y is lower alkylene and the like, and ring A is phenyl, pyrimidyl, thiazolyl, pyridyl, pyrazyl or imidazolyl, a pharmaceutically acceptable salt thereof and pharmaceutical agents containing these compounds. The compound of the present invention has superior TNF-α production inhibitory effect and/or IL-10 production promoting effect, and, since it is free of or shows only strikingly reduced expression of an effect on the central nervous system, the compound is useful as a highly safe and superior TNF-α production inhibitor an/or IL-10 production promoter and is useful as an agent for the prophylaxis or treatment of various diseases caused by abnormal TNF-α production, diseases curable with IL-10, such as chronic inflammatory diseases, acute inflammatory diseases, inflammatory diseases due to infection, autoimmune diseases, allergic diseases, and TNF-α mediated diseases.

Novel DMARDs on the basis of a new concept of dual cytokine regulation, TNF-α suppression and IL-10 augmentation

A series of arylpiperazine derivatives was synthesized to obtain agents showing apparent therapeutic effects in a chronic inflammatory animal model, starting from a lead possessing potent dual cytokine regulatory activity in vivo. We found a pyrimidylpipe